Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a ...

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today ...

First-in-human trial of Capricor’s StealthX™ vaccine initiated under HHS’s Project NextGenTrial conducted and funded by the ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal ...

The multicenter clinical study (NCT06908928) aims to evaluate the efficacy and safety of BFv in TNBC patients previously treated with a taxane and an antibody-drug conjugate with a topoisomerase ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Stoke Therapeutics and Biogen have dosed the first subject in the Phase III EMPEROR trial of zorevunersen for Dravet syndrome ...

Omer Trivizki discusses promising results of VOY-101, a gene therapy for geographic atrophy, highlighting safety and next ...

Provided by PR NewswireJul 9, 2025, 3:14:00 AM First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 ...

Vico Therapeutics announced that the first patient has been dosed in a phase 1/2a study evaluating VO659, an investigational antisense oligonucleotide for Huntington’s disease and ...

Allay Therapeutics’ Japanese partner Maruishi Pharmaceutical has also dosed the first patient in January in a Phase I/II multi-center open-label safety study of ATX101 in Japan.